Key Takeaways CMS has prohibited Medicaid and CHIP reimbursement for certain types of gender-affirming healthcare for minors, including puberty blockers, cross-sex hormone therapy and surgical intervention, effective October 13, 2026. The Final Rule’s prohibitions only apply if the purpose of treatment is gender-affirming healthcare. Federal funds remain available for the same drugs and therapies when … Continued
| less than a minute read
CMS Imposes Prohibition on Federal Medicaid and CHIP Payment for Certain Gender-Affirming Healthcare for Minors: What Providers Need to Know

/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-08-20-13-23-01-696-6a86ffb53a308039a685aeaa.jpg)
/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-08-19-17-02-51-484-6a85e1bb066c09d67f2909c7.jpg)
/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-08-14-13-26-30-982-6a7f1786ab32e384aeb756f2.jpg)
/Passle/68adf618fb5257a156b22ed3/SearchServiceImages/2026-08-14-13-24-57-387-6a7f1729235f0d4cbaa4dfbf.jpg)